PKM2在肝癌组织中的表达及与临床病理特征的关系

摘要

目的：探讨 M2型丙酮酸激酶同工酶（PKM2）在人肝癌组织与癌旁组织中的表达及其与临床病理特征之间的关系。方法采用免疫组化方法对手术确诊的144例肝癌及癌旁组织标本进行 PKM2检测，并分析其表达与临床病理、生化之间的关系。结果肝癌组织中 PKM2阳性表达为53．5％，癌旁组织中 PKM2阳性表达为27．1％；PKM2的表达与γ－谷氨酰转移酶、碱性磷酸酶、肿瘤大小和分化程度呈显著相关（P ＜0．05），与性别、年龄、肝炎病史、肝硬化病史、甲胎蛋白、谷草转氨酶、谷丙转氨酶以及临床分期无显著相关（P ＞0．05）。结论PKM2在肝癌组织中的表达明显高于癌旁组织，且其表达与肝癌的肿瘤大小和分化程度密切相关，有望成为肝癌诊断的新指标及潜在的治疗靶点。%Objective To explore the expression of PKM2 and clinical significance in hepatocellular carcinoma (HCC).Methods The expression of PKM2 in 144 surgically resected specimens of hepatocellular carcinoma cancer was evaluated by immunohistochemi-cal, and the clinical and pathological features were further analyzed.Results The positive rate for PKM2 expression in hepatocellular carcinoma tissues and paraneoplastic tissues was 53.5% and 27.1%, respectively.The expression of PKM2 was positively correlated with tumor size, pathological grade and the expression of γ-GT and ALP(P <0.05).However, the expression of PKM2 was not cor-related with the patients gender, age, hepatitis history, liver cirrhosis, AFP, AST, ALT and clinical stages(P >0.05).Conclusions The expression level of PKM2 in HCC tissues is significantly higher than the paraneoplastic tissues, and the expression of PKM2 was correlated with tumor size and pathological grade, suggested that PKM2 may serve as a valuable biomarker for diagnosing and a poten-tial target for treating HCC.